Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Bioactive Compounds in the Prevention of Chronic Diseases
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Bioactive Compounds in the Prevention of Chronic Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 4994

Special Issue Editors

Dr. Diego A. Moreno

E-Mail Website
Guest Editor
Laboratorio de Fitoquímica y Alimentos Saludables (LabFAS), CEBAS, CSIC, Campus Universitario de Espinardo—25, E-30100 Espinardo, Murcia, Spain
Interests: phytochemicals; inflammation; obesity; health-centered agri-foods
Special Issues, Collections and Topics in MDPI journals
Dr. Antonio J. Ruiz-Alcaraz

E-Mail Website
Guest Editor
Department of Biochemistry, Molecular Biology B and Immunology, School of Medicine, University of Murcia, Regional Campus of International Excellence “Campus Mare Nostrum”, 30100 Murcia, Spain
Interests: inmune response; inflammation; immunonutrition; chronic diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Paola Maycotte

E-Mail Website
Guest Editor
Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico
Interests: cancer; metabolism; autophagy; reactive oxygen species; phytochemicals
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In order to resolve the need for a balanced and varied diet that is rich in bioactive compounds to combat the rising incidence of diseases such as obesity, diabetes, cardiovascular diseases, cancer, and osteoporosis, we are interested in breakthrough experimental and technical progress of broad interest in biology, chemistry, and medicine on Bioactive Compounds in the Prevention of Chronic Diseases.

The bioactive compounds and their known metabolites including, but not limited to, polyphenols, fatty acids, proteins, dietary fibers, etc., play a crucial role in modulating inflammation and oxidative stress, which are key factors in chronic disease development. Additionally, the search for safer and more effective therapeutics for life-threatening diseases like cancer, diabetes, and cardiovascular diseases is ongoing. We encourage authors to focus on results at the molecular level and to submit their contributions to help the scientific community and society by extension to fully understand the effectiveness of the bioactive compounds in disease management.

Dr. Diego A. Moreno
Dr. Antonio J. Ruiz-Alcaraz
Dr. Paola Maycotte
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactives
  • chronic disease
  • inflammation
  • oxidative stress
  • obesity
  • diabetes
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 2921 KiB  
Article
Assessing the Anti-Inflammatory and Antioxidant Activity of Mangiferin in Murine Model for Myocarditis: Perspectives and Challenges
by Alexandra Popa, Lia-Oxana Usatiuc, Iuliu Calin Scurtu, Raluca Murariu, Alexandra Cofaru, Romelia Pop, Flaviu Alexandru Tabaran, Luciana Madalina Gherman, Dan Valean, Alexandru Cristian Bolundut, Rares Ilie Orzan, Ximena Maria Muresan, Andreea Georgiana Morohoschi, Sanda Andrei, Cecilia Lazea and Lucia Agoston-Coldea
Int. J. Mol. Sci. 2024, 25(18), 9970; https://doi.org/10.3390/ijms25189970 - 16 Sep 2024
Cited by 1 | Viewed by 1580
Abstract
Myocarditis is a major cause of heart failure and death, particularly in young individuals. Current treatments are mainly symptomatic, but emerging therapies focus on targeting inflammation and fibrosis pathways. Natural bioactive compounds like flavonoids and phenolic acids show promising anti-inflammatory and antioxidant properties. [...] Read more.
Myocarditis is a major cause of heart failure and death, particularly in young individuals. Current treatments are mainly symptomatic, but emerging therapies focus on targeting inflammation and fibrosis pathways. Natural bioactive compounds like flavonoids and phenolic acids show promising anti-inflammatory and antioxidant properties. Corticosteroids are frequently employed in the treatment of autoimmune myocarditis and appear to lower mortality rates compared to conventional therapies for heart failure. This study aims to explore the effects of Mangiferin on pro-inflammatory cytokine levels, nitro-oxidative stress markers, histopathological alterations, and cardiac function in experimental myosin-induced autoimmune myocarditis. The effects were compared to Prednisone, used as a reference anti-inflammatory compound, and Trolox, used as a reference antioxidant. The study involved 30 male Wistar–Bratislava rats, which were randomly divided into five groups: a negative control group (C−), a positive control group with induced myocarditis using a porcine myosin solution (C+), three groups with induced myocarditis receiving Mangiferin (M), Prednisone (P), or Trolox (T) as treatment. Cardiac function was evaluated using echocardiography. Biochemical measurements of nitro-oxidative stress and inflammatory markers were conducted. Finally, histopathological changes were assessed. At echocardiography, the evaluation of the untreated myocarditis group showed a trend toward decreased left ventricular ejection fraction (LVEF) but was not statistically significant, while all treated groups showed some improvement in LVEF and left ventricular fraction shortening (LVFS). Significant changes were seen in the Mangiferin group, with lower end-diastolic left ventricular posterior wall (LVPWd) by day 21 compared to the Trolox group (p < 0.001). In the first week of the experiment, levels of interleukins (IL)-1β, IL-6, and tumour necrosis factor (TNF)-α were significantly higher in the myosin group compared to the negative control group (p < 0.001, p < 0.001, p < 0.01), indicating the progression of inflammation in this group. Treatment with Mangiferin, Prednisone, and Trolox caused a significant reduction in IL-1β compared to the positive control group (p < 0.001). Notably, Mangiferin resulted in a superior reduction in IL-1β compared to Prednisone (p < 0.05) and Trolox (p < 0.05). Furthermore, Mangiferin treatment led to a statistically significant increase in total oxidative capacity (TAC) (p < 0.001) and a significant reduction in nitric oxide (NOx) levels (p < 0.001) compared to the negative control group. Furthermore, when compared to the Prednisone-treated group, Mangiferin significantly reduced NOx levels (p < 0.001) and increased TAC levels (p < 0.001). Mangiferin treatment significantly lowered creatine kinase (CK) and aspartate aminotransferase (AST) levels on day 7 (p < 0.001 and p < 0.01, respectively) and reduced CK levels on day 21 (p < 0.01) compared to the untreated group. In the nontreated group, the histological findings at the end of the experiment were consistent with myocarditis. In the group treated with Mangiferin, only one case exhibited mild inflammatory infiltrates, represented by mononucleated leukocytes admixed with few neutrophils, with the severity graded as mild. Statistically significant correlations between the grades (0 vs. 1–2) and the study groups have been highlighted (p < 0.005). This study demonstrated Mangiferin’s cardioprotective effects in autoimmune myocarditis, showing reduced oxidative stress and inflammation. Mangiferin appears promising as a treatment for acute myocarditis, but further research is needed to compare its efficacy with other treatments like Trolox and Prednisone. Full article
(This article belongs to the Special Issue Bioactive Compounds in the Prevention of Chronic Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 1109 KiB  
Review
Research Progress on Anti-Inflammatory Mechanism of Inula cappa
by Ningning Wu, Siqi Wang, Yuqian Zhang and Siming Wang
Int. J. Mol. Sci. 2025, 26(5), 1911; https://doi.org/10.3390/ijms26051911 - 23 Feb 2025
Viewed by 547
Abstract
The incidence of various inflammatory diseases has remained high. Inula cappa is a kind of Chinese herbal medicine with a wide range of pharmacological uses and application value. It has anti-inflammatory, antibacterial, antioxidant, hepatoprotective and other pharmacological activities. The monomeric compounds that have [...] Read more.
The incidence of various inflammatory diseases has remained high. Inula cappa is a kind of Chinese herbal medicine with a wide range of pharmacological uses and application value. It has anti-inflammatory, antibacterial, antioxidant, hepatoprotective and other pharmacological activities. The monomeric compounds that have been confirmed to have anti-inflammatory effects are luteolin, chrysoerilol, artemetin, chlorogenic acid, neochlorogenic acid, cryptchlorogenic acid, isochlorogenic acid A, isochlorogenic acid B, isochlorogenic acid C and 1,3-O-dicaffeoylquinic acid. This article introduces the relationship between Inula cappa and inflammation, the anti-inflammatory components of I. cappa, the modulation of each component on the inflammatory transduction signal pathway, and the TLR2/MyD88/NF-KB anti-inflammatory signaling pathway, providing a theoretical basis for anti-inflammatory research on and clinical medication using Inula cappa. Full article
(This article belongs to the Special Issue Bioactive Compounds in the Prevention of Chronic Diseases)
►▼ Show Figures

Figure 1

26 pages, 3353 KiB  
Review
Potential Use of Selected Natural Compounds with Anti-Biofilm Activity
by Dagmara Fydrych, Jagoda Jeziurska, Jana Wełna and Joanna Kwiecińska-Piróg
Int. J. Mol. Sci. 2025, 26(2), 607; https://doi.org/10.3390/ijms26020607 - 13 Jan 2025
Viewed by 1460
Abstract
Antibiotic resistance in microorganisms is an escalating global concern, exacerbated by their formation of biofilms, which provide protection through an extracellular matrix and communication via quorum sensing, enhancing their resistance to treatment. This situation has driven the search for alternative approaches, particularly those [...] Read more.
Antibiotic resistance in microorganisms is an escalating global concern, exacerbated by their formation of biofilms, which provide protection through an extracellular matrix and communication via quorum sensing, enhancing their resistance to treatment. This situation has driven the search for alternative approaches, particularly those using natural compounds. This study explores the potential of phytochemicals, such as quercetin, apigenin, arbutin, gallic acid, proanthocyanidins, and rutin, known for their antibacterial properties and ability to inhibit biofilm formation and disrupt mature biofilms. The methods used in this study included a comprehensive review of current literature assessing the bioavailability, distribution, and effective concentrations of these compounds in treating biofilm-associated infections. The results indicate that these phytochemicals exhibit significant antibacterial effects, reduce biofilm’s structural integrity, and inhibit bacterial communication pathways. Moreover, their potential use in combination with existing antibiotics may enhance therapeutic outcomes. The findings support the conclusion that phytochemicals offer promising additions to anti-biofilm strategies and are capable of complementing or replacing conventional treatments, with appropriate therapeutic levels and delivery mechanisms being key to their effectiveness. This insight underscores the need for further research into their clinical applications for treating infections complicated by biofilms. Full article
(This article belongs to the Special Issue Bioactive Compounds in the Prevention of Chronic Diseases)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop